pic
Business Climatepic
Exceptional Workforcepic
Incentives and Benefitspic
Information for Investorspic
Business Sectorspic
Success Storiespic
By Region
Home Grown Successes
Check Point
Given Imaging
InSightec
Iscar Metal Working Companies (IMC)
Kamada
Keter Group
Netafim
Ormat Technologies
RAD Group
Teva Pharmaceutical Industries
ZAG Industries
Multinationals
About Uspic

NEWS
EVENTS
KAMADA
Kamada - High Quality pharmaceuticals

"With a world-leading development and production facility, Kamada’s vision of developing life-saving biopharmaceuticals is rapidly becoming a reality," Ralph Hahn, Co-Founder of Kamada.

Kamada Ltd is a biopharmaceutical company developing, producing and marketing a line of specialty, life-saving therapeutics using its proprietary chromatographic purification technology.

 

 

Highlights

 

1991 - Kamada was founded in Israel and by 1998, was manufacturing 10 products in 15 countries.

 

 

2004 - Kamada received Orphan Drug Designation for inhaled AAT(Alpha-1 Antitrypsin)  by the FDA and EMEA. AAT became Kamada's flagship product for the treatment of various lung disorders.

 

2005 - Kamada became Israel's first public biopharmaceutical company.

 

2006 - A strategic agreement was reached with Germany's PARI  Pharma to develop inhalation of AAT.

 

2007 - Kamada was granted a US patent for Transferrin.

 

2007 - Intravenous AAT Phase III clinical trials began in the US ; EMEA approved 

inhaled AAT Phase-II-III clinical plans and FDA approval was granted for KamRab,

an anti-rabies immune drug Phase II-III clinical plans.

 

2008 - Kamada received a European patent for its AAT Manufacturing Process.

 

2008 - Kamada and PARI have entered a new licensing agreement to use PARIs eFlow electronic drug nebulizer with additional indications for Kamada's AAT drug.

 

2008 - Aerosolized AAT is currently undergoing Phase II clinical trials for the treatment of Cystic Fibrosis and Bronchiectasis.

                                                     

                                  

Returns and Investments

2008-Kamada entered into a $ 4 Million private equity investment agreement with Shavit Capital Fund.

2008-Kamada signed a $20M financing agreement with US based Hercules Technology Growth Capital, Inc.

2008-Total revenues for 2007 were $13.5 million (S&P)

 


Last modified: 7/20/2008 pic